Your browser doesn't support javascript.
loading
Impact of comorbidity on medication use in elderly patients with cardiovascular diseases: the OCTOCARDIO study.
Moubarak, Ghassan; Ernande, Laura; Godin, Matthieu; Cazeau, Serge; Vicaut, Eric; Hanon, Olivier; Zuily, Stephane; Tournoux, Francois; Danchin, Nicolas; Derumeaux, Genevieve; Mechulan, Alexis.
Afiliación
  • Moubarak G; Groupe Hospitalier Paris Saint-Joseph, Paris, France. ghassan.moubarak@gmail.com
Eur J Prev Cardiol ; 20(4): 524-30, 2013 Aug.
Article en En | MEDLINE | ID: mdl-22447578
ABSTRACT

BACKGROUND:

Recommended medications are under-prescribed in elderly patients with atrial fibrillation (AF), coronary artery disease (CAD), and congestive heart failure (CHF). The relationship between under-prescribing and comorbidity is unclear.

DESIGN:

Single-day observational study.

METHODS:

Analysis of medications taken by patients aged 80 years or over at the time of their admission to cardiology units of 32 French hospitals. Comorbidity was measured using the Charlson comorbidity index (CCI).

RESULTS:

The study included 510 patients (57% men, mean age 85 years). History of AF, CHF, and CAD was present in 213 (42%), 199 (39%), and 187 (37%) patients, respectively. CCI was 0 in 110 (22%), 1-2 in 215 (42%), and ≥3 in 185 (36%) patients. Vitamin K antagonists (VKA) were prescribed to 105 (49%) and aspirin to 86 (40%) patients with AF. CCI did not influence VKA prescription but influenced aspirin use, with lower prescription rates in patients with CCI 1-2 than CCI 0 or CCI ≥3 (p = 0.02). In CHF, angiotensin-converting enzyme inhibitors (ACEI) and ß-blockers were prescribed to 80 (40%) and 96 (48%) patients, respectively. Rates of prescription of ACEI, ß-blockers, statins, and aspirin in patients with CAD were 43%, 56%, 56%, and 66%, respectively. CCI level did not influence any medication use in CHF and CAD.

CONCLUSION:

Even in the absence of comorbidity, elderly patients with major cardiovascular diseases are denied from indicated medical treatments probably because of their age alone. Implementing measures to enhance awareness of treatment benefits and promote appropriate prescribing is necessary.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Cardiovasculares / Enfermedades Cardiovasculares Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged80 / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Eur J Prev Cardiol Año: 2013 Tipo del documento: Article País de afiliación: Francia Pais de publicación: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Cardiovasculares / Enfermedades Cardiovasculares Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged80 / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Eur J Prev Cardiol Año: 2013 Tipo del documento: Article País de afiliación: Francia Pais de publicación: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM